These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3055876)

  • 21. [Auranofin in the treatment of rheumatoid arthritis. Report of 63 cases].
    Tao XL; Dong Y; Zhang NZ
    Zhonghua Nei Ke Za Zhi; 1987 Jul; 26(7):390-3, 444. PubMed ID: 3428027
    [No Abstract]   [Full Text] [Related]  

  • 22. [Comparison between auranofin and chloroquine in the therapy of rheumatoid arthritis].
    Gallo M; La Montagna G; Valentini G
    Clin Ter; 1986 Nov; 119(4):293-8. PubMed ID: 3802739
    [No Abstract]   [Full Text] [Related]  

  • 23. Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial.
    Bombardier C; Ware J; Russell IJ; Larson M; Chalmers A; Read JL
    Am J Med; 1986 Oct; 81(4):565-78. PubMed ID: 3532786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Auranofin therapy in rheumatoid arthritis.
    Bernhard GC
    J Lab Clin Med; 1982 Aug; 100(2):167-77. PubMed ID: 6808066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. One-year experience in patients treated with auranofin following completion of a parallel, controlled trial comparing auranofin, gold sodium thiomalate, and placebo.
    Williams HJ; Dahl SL; Ward JR; Karg M; Willkens RF; Meenan RF; Altz-Smith M; Clegg DO; Mikkelsen WM; Kay DR
    Arthritis Rheum; 1988 Jan; 31(1):9-14. PubMed ID: 3125841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective trial comparing the use of sulphasalazine and auranofin as second line drugs in patients with rheumatoid arthritis.
    Porter D; Madhok R; Hunter JA; Capell HA
    Ann Rheum Dis; 1992 Apr; 51(4):461-4. PubMed ID: 1350192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of phenytoin with auranofin and chloroquine in rheumatoid arthritis--a double blind study.
    Rao UR; Naidu MU; Kumar TR; Shobha U; Askar MA; Ahmed N; Sarada P; Venubabu K; Shantaram V; Menon GN
    J Rheumatol; 1995 Jul; 22(7):1235-40. PubMed ID: 7562751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical effectiveness and tolerance of auranofin in patients with chronic polyarthritis. Results of a multicenter long-term study].
    Klein G; Schwann H; Mirtl B; Thumb N; Mayerhofer F; Singer F; Tausch G; Gaismayer K; Rieder H; Hartweger A
    Z Rheumatol; 1988; 47(5):342-6. PubMed ID: 3149087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Auranofin: a unique oral chrysotherapeutic agent.
    Blodgett RC; Heuer MA; Pietrusko RG
    Semin Arthritis Rheum; 1984 Feb; 13(3):255-73. PubMed ID: 6427927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of auranofin in patients with active early rheumatoid arthritis.
    Itokazu M; Matsunaga T; Oshita Y
    Clin Ther; 1995; 17(1):60-73. PubMed ID: 7758062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Auranofin and quality of life.
    Morgan GJ
    Scand J Rheumatol; 1988; 17(5):363. PubMed ID: 3212406
    [No Abstract]   [Full Text] [Related]  

  • 32. Dose response studies and longterm evaluation of auranofin in rheumatoid arthritis.
    Champion GD; Cairns DR; Bieri D; Adena MA; Browne CD; Cohen ML; Day RO; Edmonds JP; Graham GG; de Jager J
    J Rheumatol; 1988 Jan; 15(1):28-34. PubMed ID: 3280795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Auranofin. The Pharmacy Department, the Amalgamated Melbourne and Essendon Hospitals.
    Aust Nurses J; 1988 Jun; 17(11):25-6. PubMed ID: 3421870
    [No Abstract]   [Full Text] [Related]  

  • 34. [Gold preparations in therapy of rheumatoid and psoriatic arthritis].
    Nasonova VA; Lukina GV; Sigidin IaA; Badokin VV
    Ter Arkh; 2003; 75(5):88-90. PubMed ID: 12847908
    [No Abstract]   [Full Text] [Related]  

  • 35. A three year follow up of patients allocated to placebo, or oral or injectable gold therapy for rheumatoid arthritis.
    Capell HA; Lewis D; Carey J
    Ann Rheum Dis; 1986 Sep; 45(9):705-11. PubMed ID: 3094463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review of auranofin, an oral chrysotherapeutic agent.
    Delafuente JC; Osborn TG
    Clin Pharm; 1984; 3(2):121-7. PubMed ID: 6426843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Auranofin and gold sodium thiomalate in the treatment of rheumatoid arthritis: a one-year, double-blind, comparative multicenter study.
    Schattenkirchner M; Bröll H; Kaik B; Müller-Fassbender H; Rau R; Zeidler H
    Klin Wochenschr; 1988 Feb; 66(4):167-74. PubMed ID: 3131571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost effectiveness of auranofin: results of a randomized clinical trial.
    Thompson MS; Read JL; Hutchings HC; Paterson M; Harris ED
    J Rheumatol; 1988 Jan; 15(1):35-42. PubMed ID: 3127585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Auranofin, methotrexate, but no placebo: comment on the article by Williams et al.
    Epstein WV; Criswell LA
    Arthritis Rheum; 1992 Nov; 35(11):1406-7. PubMed ID: 1445469
    [No Abstract]   [Full Text] [Related]  

  • 40. Influence of auranofin on lymphocyte membrane fluidity in rheumatoid arthritis. A fluorescence polarization study.
    Beccerica E; Piergiacomi G; Curatola G; Ferretti G
    Scand J Rheumatol; 1989; 18(6):413-8. PubMed ID: 2617230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.